In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.

Merck Company published an article in the Journal of Medicinal Chemistry (JMC) on the 20th of this month, reporting on the discovery process of LRRK2 inhibitor MK1468.

this approach brings new hope that we can finally address the growing concern of obesity worldwide.

For most patients with severe depression, monoamine-targeted first or second-line treatments often cannot achieve sufficient therapeutic effects.